Find answers in your patient's blood

Targeted liquid biopsy for all advanced solid tumors to support your clinical decisions

58 genes

SNVs, Indels

TERT promoter

Unusual splicing

Gene translocations

OncoSELECT™
by OncoDNA

WHY **CHOOSE** ONCOSELECT®?

OncoSELECT® helps optimize treatment strategies across all advanced solid tumors from just two tubes of blood, and matches patients with **targeted therapy**, **hormone therapy** and **potential clinical trials** to improve your patients' clinical outcomes. Rely on a blood-based biomarker-informed approach to make quick and personalized treatment plans for your patient.

IN WHAT **SCENARIOS** IS ONCOSELECT® USEFUL?

When your patients cannot have their tumor biopsied, when their tumor tissue sample is too old or too scarce for comprehensive biomarker testing, OncoSELECT® is the perfect alternative to support your clinical decisions thanks to a **fast** and **minimally invasive** analysis of circulating tumor DNA from a blood sample.

OncoSELECT® is available for **all advanced solid tumors in adults** and recommended for **stage 3 or 4** cancer patients when:

- Patient is receiving chemotherapy in neoadjuvant setting. OncoSELECT® may be used to inform on the **patient's response to treatment**.
- Patient is relapsing under current therapy. OncoSELECT® may be used after a line of treatment to **identify if the patient developed resistant mutations**.
- Patient is wild type for specific genes related to their cancer type based on the analysis of their solid biopsy. OncoSELECT® may be performed before the first line of treatment to **assess the heterogeneity of the disease**.

GENE **PANEL**

Whole exons

APC	FBXW7	PIK3CA
ARID1A	FGFR2	PTEN
ATM	FGFR3	RET
BRCA1	H3F3A	SMAD4
BRCA2	HRAS	SMO
CCND1	KRAS	STK11
CCNE1	MET	TP53
ERBB2	NRAS	VHL
	PALB2	

Hotspots

AKT1	ESR1	MPL
ALK	EZH2	mTOR
AR	GNA11	NF1
ARAF	GNAQ	NTRK1
BRAF	GNAS	POLE
CTNNB1	IDH1	PDGFRA
DDR2	IDH2	ROS1
EGFR	KIT	TERT promoter

Genes associated with translocatons

ALK	ETV5	MET
BRAF	ETV6	NRG1
BRCA1	EWSR1	NTRK1
BRCA2	FGFR1	NTRK2
CD74	FGFR2	RAF1
EGFR	FGFR3	RET
ETV4	KIT	ROS1

Unusual splicing genes

BRCA1
BRCA2
MET

ONCOSELECT® **STEP BY STEP**

Our teams are at hand to assist you every step of the way – from discussing the relevance of the test for your patient and easing the sample collection to understanding the clinical recommendations listed in the report.



A **63-year-old man** with **stage IV prostate cancer** (mCRPC), **metastasized** to lung, lymph node, bone

OncoSELECT allowed the identification of an **AR V890M** variant which explained the lack of clinical benefit of the previous hormonal therapies. Moreover, the detection of **BRCA2 somatic** and **ATM R3008C** variants led to the prescription of **olaparib** with a complete response, and no relapse was identified for the last 6 months.

A **55-year-old non-smoker male** was diagnosed with metastatic non-small-cell lung carcinoma (**NSCLC**)

Oncologist requested to perform a liquid biopsy test since the lung needle biopsy obtained was of limited quantity. The patient was progressing under erlotinib and OncoSELECT allowed the detection of **EGFR T790M** variant. The detection of this variant led the oncologist to choose **osimertinib** which resulted in good response without any known relapse so far.

A **43-year-old woman** with s**tage IV breast HR cancer**, with recent relapse

OncoSELECT was performed because no solid biopsy was available for this patient. It allowed the identification of **ESR1 L536Q** and **PIK3CA E545K** mutations. Based on these biomarkers, it was decided to prescribe **alpelisib** in combination with **fulvestrant**, an FDA-approved treatment, to the patient. The patient responded well to the treatment without any relapse in the last 6 months.

ONCOSELECT® **REPORT**

The OncoSELECT report helps you **flag potential resistance mechanisms** and **optimize treatment strategies**.

Each report:

- Contains the patient's medical information (patient diagnosis, tumor type and stage, blood draw date ...)
- Reveals all actionable variants and their biological and therapeutical classifications according to ACMG/AMP guidelines
- Reveals a patient's receptiveness to targeted therapy or hormonal therapy
- Details all relevant recruiting clinical trials with detailed information on the drug development stage and its clinical benefit for your patient.



Contact us to discuss your patient case

customersupport@oncodna.com +32 (0)71 18 35 00